Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03350633 (ClinicalTrials.gov)	November 1, 2017	10/11/2017	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders	Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial	Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica	Drug: Tocilizumab Injection;Drug: Azathioprine	Tianjin Medical University General Hospital	NULL	Completed	18 Years	N/A	All	118	Phase 2/Phase 3	China
2	NCT03062579 (ClinicalTrials.gov)	February 1, 2017	13/2/2017	A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD	Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)	Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica;Devic's Disease	Drug: Tocilizumab	Fu-Dong Shi	NULL	Completed	18 Years	N/A	All	10	Phase 1/Phase 2	China
3	JPRN-UMIN000022201	2016/01/10	04/05/2016	The efficacy and safety of tocilizumab in patients with neuromyelitis optica	The efficacy and safety of tocilizumab in patients with neuromyelitis optica - The efficacy and safety of tocilizumab in patients with neuromyelitis optica	neuromyelitis optica	Tocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years.	Department of Neurology, Shimane University Hospital	NULL	Complete: follow-up complete	20years-old	74years-old	Male and Female	3	Not selected	Japan
4	JPRN-UMIN000012705	2014/01/07	07/01/2014	The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis		Relapsing-remitting multiple sclerosis	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 2 years.	Department of Immunology, National Institute of Neuroscience, NCNP	NULL	Recruiting	20years-old	65years-old	Male and Female	10	Not applicable	Japan
5	JPRN-jRCTs031180346	02/12/2013	18/03/2019	Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosis	The efficacy and safety of an anti-interluekin-6 receptor antibody in multiple sclerosis	multiple sclerosis;D009103	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight.	Yamamura Takashi	NULL	Complete	>= 20age old	<= 65age old	Both	6	N/A	Japan
6	JPRN-jRCTs031180152	04/06/2012	25/02/2019	Tocilizumab in patients with neuromyelitis optica	The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter study - Tocilizumab in patients with neuromyelitis optica	Neuromyelitis optica;D009471	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.	Yamamura Takashi	NULL	Complete	>= 20age old	<= 65age old	Both	20	N/A	Japan
7	JPRN-UMIN000007866	2012/05/01	01/05/2012	The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study		neuromyelitis optica	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 years.	Department of Immunology, National Institute of Neuroscience, NCNP	Department of Neurology, Kinki University Faculty of Mediceine	Complete: follow-up continuing	20years-old	65years-old	Male and Female	15	Not applicable	Japan
8	JPRN-UMIN000005889	2011/07/01	08/07/2011	The safety and efficacy of tocilizumab in patients with neuromyelitis optica		neuromyelitis optica	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.	Department of Immunology, National Institute of Neuroscience, NCNP	NULL	Complete: follow-up complete	20years-old	65years-old	Male and Female	3	Not applicable	Japan